[PubMed Central ID: PMC6167285]
Here's How to Break Through - REJUV, accessed April 23, 2025, Wegovy timeline: what to expect - Numan, accessed April 23, 2025, Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes, accessed April 23, 2025, Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and MetaAnalysis of Direct Comparative Studies - PubMed Central, accessed April 23, 2025, SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial, accessed April 23, 2025, Lilly's tirzepatide superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs

Many Alexandria residents prioritize preventative care because they understand that feeling your best allows you to enjoy everything the community has to offer, from waterfront walks along the Potomac River to spending quality time with family and friends
Keeping that distinction clear between what has been characterized in research and what has been demonstrated to be safe and effective in human patients is the single most important thing for a clinician to understand about these compounds
The third error is recommending that patients "round to the nearest unit" when a calculated dose falls between markings (for example, 12.5 units when the syringe only has 1-unit increments)